𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Effect of CYP2D6 polymorphisms on breast cancer recurrence

✍ Scribed by Phuong K. Morrow; Ruben Serna; Kristine Broglio; Lajos Pusztai; D. Michelle Nikoloff; Grantland R. Hillman; Marcel Fontecha; Rui Li; Laura Michaud; Gabriel Hortobagyi; Ana M. Gonzalez-Angulo

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
768 KB
Volume
118
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CYP2D6 polymorphisms and the impact on t
CYP2D6 polymorphisms and the impact on tamoxifen therapy
✍ Jacob N. Beverage; Tristan M. Sissung; Amy M. Sion; Romano Danesi; William D. Fi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB

The cytochrome P450 2D6 (CYP2D6) is an enzyme known to metabolize a variety of xenobiotics and drugs. Inter-individual variation in the metabolic capacity of this enzyme has been extensively studied and associations with genotype have been established. Genetic polymorphisms have been grouped as nonf

Genetic polymorphisms of CYP2D6*10 and C
Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen
✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions

Effects of the CYP2D6*10 alleles and co-
Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia
✍ Tatsuhiko Yagihashi; Masafumi Mizuno; Bun Chino; Yuji Sato; Kei Sakuma; Toru Tak 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

## Abstract ## Objective Risperidone is converted to 9‐hydroxyrisperidone by CYP2D6. Two parameters were used to examine the influences of CYP2D6 polymorphism and of co‐medication on risperidone metabolism: the risperidone:9‐hydroxyrisperidone concentration ratio (R:9‐OHR ratio) and the sum of the